TY - JOUR
T1 - Management of prostate cancer in older patients
AU - Narita, Shintaro
AU - Hatakeyama, Shingo
AU - Sakamoto, Shinichi
AU - Kato, Takuma
AU - Inokuchi, Juichi
AU - Matsui, Yoshiyuki
AU - Kitamura, Hiroshi
AU - Nishiyama, Hiroyuki
AU - Habuchi, Tomonori
N1 - Funding Information:
Japan Society for the Promotion of Science (JSPS) (KAKENHI grant no. 19K16706, 19K09663.
Publisher Copyright:
© 2022 The Author(s).
PY - 2022/6/1
Y1 - 2022/6/1
N2 - The incidence of prostate cancer among older men has increased in many countries, including Asian countries. However, older patients are ineligible for inclusion in large randomized trials, and the existing guidelines for the management of patients with prostate cancer do not provide specific treatment recommendations for older men. Therefore, generation of evidence for older patients with prostate cancer is a key imperative. The International Society of Geriatric Oncology has produced and updated several guidelines for management of prostate cancer in older men since 2010. Regarding localized prostate cancer, both surgery and radiotherapy are considered as feasible treatment options for intermediate- and high-risk prostate cancer even in older men, whereas watchful waiting and active surveillance are useful options for a proportion of these patients. With regard to advanced disease, androgen-receptor axis targets and taxane chemotherapy are standard treatment modalities, although dose modification and prevention of adverse events need to be considered. Management strategy for older patients with prostate cancer should take cognizance of not only the chronological age but also psychological and physical condition, socio-economic status and patient preferences. Geriatric assessment and patient-reported health-related quality of life are important tools for assessing health status of older patients with prostate cancer; however, there is a paucity of evidence of the impact of these tools on the clinical outcomes. Personalized management according to the patient's health status and tumour characteristics as well as socio-economic condition may be necessary for treatment of older patients with prostate cancer.
AB - The incidence of prostate cancer among older men has increased in many countries, including Asian countries. However, older patients are ineligible for inclusion in large randomized trials, and the existing guidelines for the management of patients with prostate cancer do not provide specific treatment recommendations for older men. Therefore, generation of evidence for older patients with prostate cancer is a key imperative. The International Society of Geriatric Oncology has produced and updated several guidelines for management of prostate cancer in older men since 2010. Regarding localized prostate cancer, both surgery and radiotherapy are considered as feasible treatment options for intermediate- and high-risk prostate cancer even in older men, whereas watchful waiting and active surveillance are useful options for a proportion of these patients. With regard to advanced disease, androgen-receptor axis targets and taxane chemotherapy are standard treatment modalities, although dose modification and prevention of adverse events need to be considered. Management strategy for older patients with prostate cancer should take cognizance of not only the chronological age but also psychological and physical condition, socio-economic status and patient preferences. Geriatric assessment and patient-reported health-related quality of life are important tools for assessing health status of older patients with prostate cancer; however, there is a paucity of evidence of the impact of these tools on the clinical outcomes. Personalized management according to the patient's health status and tumour characteristics as well as socio-economic condition may be necessary for treatment of older patients with prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85131223481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131223481&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyac016
DO - 10.1093/jjco/hyac016
M3 - Review article
C2 - 35217872
AN - SCOPUS:85131223481
SN - 0368-2811
VL - 52
SP - 513
EP - 525
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 6
ER -